Andrew Briskin

Jul 14, 2023 | diatribe.org | Andrew Briskin |Susannah Chen

Brenzavvy, a type 2 diabetes drug recently approved by the FDA, has just become commercially available at lower cost with no insurance required. Pharmaceutical company TheracosBio has announced that Brenzavvy (bexagliflozin) is now available in the US. The medication is obtainable with a prescription through Cost Plus Drugs, a company that negotiates directly with manufacturers to offer medications at a lower price. Cost Plus is offering a 30-day supply for $47.85 plus shipping and handling.

Apr 24, 2023 | diatribe.org | Andrew Briskin

Apr 17, 2023 | diatribe.org | Andrew Briskin

Apr 17, 2023 | diatribe.org | Andrew Briskin

Apr 17, 2023 | l8r.it | Andrew Briskin |April Hopcroft

Abbott has announced that its latest continuous glucose monitor, the FreeStyle Libre 3, is now covered under Medicare. Following news in April that the FDA cleared a separate handheld reader for Abbott’s latest continuous glucose monitoring (CGM) system, the FreeStyle Libre 3, Abbott has announced that the Libre 3 system is now available for people on Medicare. This announcement follows Medicare’s April 2023 expansion of CGM coverage to include people with type 2 diabetes.